Lactulose and Mounjaro: can you take them together?

Why Mounjaro slows the gut — and what the evidence shows

Tirzepatide's weight-loss effect is partly driven by slowing gastric emptying: food leaves the stomach more gradually, which extends the feeling of fullness. That same mechanism acts further along the digestive tract. Reduced gut motility means stool moves more slowly, water is reabsorbed for longer, and the result is harder, less frequent stools. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, constipation was among the gastrointestinal events recorded across participants taking tirzepatide (alongside nausea, diarrhoea and vomiting) and GI effects as a group were most noticeable after a dose increase or in the early weeks of treatment.

Understanding this mechanism matters when you are choosing how to respond. Constipation here is not primarily a dietary fibre deficit or a fluid problem (though both contribute). It is largely a transit-time issue, driven by the medicine itself. That distinction shapes which remedies are most likely to help.

Staying well hydrated is the first and simplest step. A practical habit worth building: before reaching for a laxative, check your fluid intake over the previous day, eight glasses of water sounds obvious, but most people on a reduced-calorie diet find they are eating far less fluid-rich food than before. Fibre-rich foods and gentle movement also support gut regularity, as outlined in NHS Live Well guidance on healthy weight and diet. If those measures are not enough, that is when a laxative like lactulose enters the conversation.

What lactulose does and why the interaction risk with tirzepatide is low

Lactulose is an osmotic laxative. It passes through the small intestine unchanged (the gut wall does not absorb it) and reaches the colon, where gut bacteria ferment it. The byproducts draw water into the bowel, softening stool and stimulating movement. Because lactulose stays local to the gut and does not enter systemic circulation, it has no route by which it could affect tirzepatide's receptor binding or its pharmacokinetics.

There is one practical point worth knowing. Mounjaro slows gastric emptying, and that can theoretically slow the transit of oral medicines too. For most drugs this is not clinically significant, but it is the reason your prescriber may want to know about everything you are taking alongside tirzepatide. You can read more about whether lactulose is safe to use with Mounjaro for a more detailed look at timing and dose considerations. Some people also ask about whether Mounjaro can affect lactose tolerance, which is a separate but related gut-related question that comes up alongside constipation concerns.

Stimulant laxatives, bulk-forming agents and other osmotic options are alternatives if lactulose does not suit you, but that is a conversation for a pharmacist or prescriber rather than a forum thread. People who want to understand more about where tirzepatide's mechanisms originally come from can find that context explored on the page about tirzepatide and its lizard venom origins.

When constipation on Mounjaro needs more than a laxative

Mild, transient constipation in the first weeks of tirzepatide treatment is common and usually settles. Severe or worsening abdominal pain is a different matter. In January 2026, the MHRA issued a Drug Safety Update reminding prescribers and patients that acute pancreatitis is a known, infrequent but serious side effect of GLP-1 medicines. The hallmark symptom is severe, persistent stomach pain that may spread to the back, sometimes with vomiting. That pattern should not be attributed to constipation and treated with a laxative: it warrants urgent medical attention.

Beyond pancreatitis, gallbladder problems and bowel obstruction (rare) can also present as abdominal discomfort in people on GLP-1 treatments. The working rule is simple: if gut symptoms are severe, are getting worse rather than better, or do not fit the mild-discomfort pattern you have come to recognise on tirzepatide, speak to a clinician the same day. Suspected side effects can also be reported using the MHRA Yellow Card scheme.

For everything else (the dull, sluggish, low-grade constipation that many people notice in the first month or after a dose step) lactulose is a reasonable, pharmacologically safe option to try while you discuss it with your team. People curious about the broader side-effect picture of tirzepatide, including questions about sexual health that sometimes arise during treatment, can find a dedicated overview on the page covering Mounjaro and erectile dysfunction, as well as more detail on the Mounjaro treatment page.

Getting the right clinical support for side effects

Mounjaro is a prescription-only medicine. Every repeat supply from a regulated service should come with an opportunity to flag how treatment is going, not because a form needs ticking, but because dose adjustments, side-effect management and decisions about adding other medicines are genuinely clinical calls. A prescriber who knows you are constipated may suggest adjusting the titration pace, reinforcing dietary changes, or recommending a specific laxative class ahead of a dose increase.

At nume, a GPhC-registered prescriber reviews every consultation personally. If you are already on tirzepatide and want to explore how it fits your health picture, or if you are considering starting, the right place to begin is a clinical conversation rather than a product page. Those thinking about starting treatment can learn more about the weight-loss process on Mounjaro or read a broader overview of weight management options available in the UK. For information on what our prescribers look at when they assess suitability, the frequently asked questions page covers the most common queries. When you are ready, check your eligibility with a free consultation.